Hematopoietic Stem Cell Transplantation in Late-onset X-linked Chronic Granulomatous Disease in a Female Carrier.

HSCT remains the main definitive treatment for X-linked CGD, yet older patients are at greater risk of transplant-related complications and mortality [[3]]. Recombinant interferon gamma augments phagocyte superoxide production and X-chronic granulomatous disease gene expression in X-linked variant chronic granulomatous disease. This suggests that matched HSCT with non-myeloablative conditioning with low dose busulfan and alemtuzumab, combined with an increased stem cell dose and post-transplant cyclophosphamide, may represent a curative option even in high-risk CGD patients at an advanced age. [Extracted from the article]